Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.61 |
| ▸ | DRD4 | P21917 | 13/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 11/20 | 0.54 |
| ▸ | DRD3 | P35462 | 9/20 | 0.54 |
| ▸ | HTR1A | P08908 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | HTR1D | P28221 | 1/20 | 0.49 |
| ▸ | HTR1B | P28222 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5751064 | 0.89 | FAAH (0.54) | FAAHDRD4MAPK14DRD2DRD3 | |
| SCHEMBL5755800 | 0.87 | DRD4 (0.55) | FAAHDRD4MAPK14DRD2DRD3 | |
| SCHEMBL5753042 | 0.87 | MAPT (0.57) | FAAHDRD4DRD2DRD3HTR1A | |
| SCHEMBL5750521 | 0.87 | FAAH (0.50) | FAAHDRD4MAPK14DRD2DRD3 | |
| SCHEMBL5754611 | 0.87 | MAPT (0.57) | FAAHDRD4MAPK14DRD2DRD3 | |
| SCHEMBL23964233 | 0.87 | FAAH (0.50) | FAAHDRD4MAPK14DRD2DRD3 | |
| SCHEMBL5754613 | 0.87 | FAAH (0.50) | FAAHDRD4MAPK14DRD2DRD3 | |
| SCHEMBL5751758 | 0.87 | DRD4 (0.56) | FAAHDRD4MAPK14DRD2DRD3 | |
| SCHEMBL4313225 | 0.86 | MAPK14 (0.61) | FAAHDRD4MAPK14DRD2DRD3 | |
| SCHEMBL5753867 | 0.86 | MCHR1 (0.56) | FAAHDRD4MAPK14DRD2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1309586-B1 | 4-, 5-, 6- AND 7-INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | LUNDBECK & CO AS H (DK) | 2006-03-22 | — | — | EP | claimed |
| US-6958338-B2 | 4-,5-,6-and 7-indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2005-10-25 | — | — | US | claimed |
| US-20030166665-A1 | 4-,5-,6-And 7-indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2003-09-04 | — | — | US | claimed |
| US-7105543-B2 | 4-, 5-, 6- and 7-indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2006-09-12 | — | — | US | disclosed |
| EP-1309586-B1 | 4-, 5-, 6- AND 7-INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | LUNDBECK & CO AS H (DK) | 2006-03-22 | — | — | EP | disclosed |
| US-20060004022-A1 | 4-, 5-, 6- And 7-indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2006-01-05 | — | — | US | disclosed |
| US-6958338-B2 | 4-,5-,6-and 7-indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2005-10-25 | — | — | US | disclosed |
| US-20030166665-A1 | 4-,5-,6-And 7-indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2003-09-04 | — | — | US | disclosed |
| EP-1309586-A1 | 4-, 5-, 6- AND 7-INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | H. LUNDBECK A/S (DK) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002016349-A1 | 4-, 5-, 6- AND 7-INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | H. LUNDBECK A/S (DK) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004022-A1 | 4-, 5-, 6- And 7-indole derivatives useful for the treatment of CNS disorders | HTR3C, SLC6A3, HTR6 | FAAH 257/4885DRD4 4/4885MAPK14 3618/4885 |
| US-20030166665-A1 | 4-,5-,6-And 7-indole derivatives useful for the treatment of CNS disorders | HTR3C, HTR6, SLC6A3 | FAAH 279/4885DRD4 10/4885MAPK14 3829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.